Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 14;9:16819. doi: 10.1038/s41598-019-53418-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Improvements in the neurological outcomes after OGD-PBMCs administration. (A) A significantly better functional recovery as assessed in the corner test (performed 20 times) was observed in the administration of the OGD-PBMC group compared with the vehicle-injected control group (PBS control group) and normoxic PBMC group at 28 days after cerebral ischemia; ^#P < 0.05 vs PBS control group (N = 6~8 per group). An absence of difference in functional recovery between the 5 × 10⁵ normoxic PBMCs administration group and the PBS control group was seen. In addition, no functional recovery was observed in the administration of both the 1 × 10⁵ OGD-monocytes (OGD-monocyte group) and 1 × 10⁵ OGD-PBMCs, and PBS control (N = 5~6) groups by two-way ANOVA. (B) A significantly better functional recovery as assessed in the corner test was observed in the administration of the 18 h OGD-PBMC group compared with the PBS control group. Finally, an improvement in the administration of the 6 h OGD-PBMC group was not found; ^#P < 0.05 vs PBS control group by one-way ANOVA (N = 5~6).